Therapeutic Antibodies

Monoclonal antibodies
#Aulos Bioscience #Cancer research #Immuno-oncology #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

AI-designed monoclonal antibody ‘redirects’ the immune system

Immuno-oncology company Aulos Bioscience has revealed interim results from an ongoing Phase I/II trial of monoclonal antibody AU-007 in solid tumours. The data indicate that AU-007 is well tolerated in patients with unresectable locally advanced or metastatic cancer and there are early signs of anti-tumour activity. Read More

#Cancer Research #Editor's Choice #News

#Antibodies #Antibody drug conjugate (ADC) #Apexigen #Mergers and acquisitions #Oncology #Pyxis Oncology

Pyxis Oncology to acquire antibody therapeutics company Apexigen

Pyxis Oncology has announced a definitive agreement by which it will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise… Read More

#Business & Investment #News

Adcendo Lab
#Antibodies #Antibody drug conjugate (ADC) #Biotech #Drug development #Seed funding

Financing ensures development of Adcendo’s ADC asset 

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Read More

#News

Gut microbiome
#Antibodies #Clinical trials #Destiny Pharma #Gut microbiome #Microbiology

Landmark trial data on successful gut colonisation

Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused… Read More

#News

Monoclonal antibodies
#Monoclonal antibodies #Tiziana Life Sciences #Type 1 diabetes

Tiziana develops intranasal antibody for type 1 diabetes

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. “With the FDA approval of the humanised anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for… Read More

#News

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Interview

How generative AI could improve drug discovery

Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within… Read More

#Exclusive Content

Antibody drug conjugate
#AI / data analytics / healthtech / informatics #Antibodies #Antibody drug conjugate (ADC) #Big pharma #Drug development #Precision medicine

A personal view on antibody drug development

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated,… Read More

#Exclusive Content

Antibodies
#Antibodies #Antibody-based therapeutics #Bio-Rad Laboratories #In Focus Report #Monoclonal antibodies

DDW In Focus e-report on the future of antibody-based drugs

Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.  This report will:   Provide an overview of the monoclonal… Read More

#News

#Antibodies #Drug discovery #Events #High throughput screening #Protein inhibitor

Symposium: Unlock high-throughput biology

The Carterra 2023 Symposia Series ‘Unlocking High-Throughput Biology and Drug Discovery’ is now open for registrations. Join industry-leading scientists from GSK, Oxford University, LifeArc, Alloy Therapeutics, Sanofi, and Carterra on April 19, 2023 in Cambridge, UK for this one-day, science-filled experience. Learn about the current advancements… Read More

#News

Hospital patient on ventilator
#Covid-19 #Covid-19 treatment #FDA #InflaRx #Monoclonal antibodies

FDA okays Gohibic for emergency use in Covid-19 patients

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or… Read More

#News #Trending News

#Biologics #Biology #Biotechnology #Drug development #Therapeutics

Next-generation pipeline for treating mast cell driven diseases 

Granular Therapeutics, a UK-based biotech company specialising in precision biologic therapies for treating mast cell driven disorders, announced clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies.  Granular Therapeutics has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #DDW Highlights podcast #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

This week in drug discovery (27-31 March)

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The… Read More

#News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

Cholesterol test
#Heart disease #Monoclonal antibodies #Phase I trial #Vaccines #Vaxxinity

LDL cholesterol vaccine ‘could be a game-changer’

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. The drug works by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). “We’re… Read More

#Editor's Choice #News

Bacteria in Petri dishes
#Antibiotics #Antibodies #Antimicrobial resistance (AMR) #Antimicrobials #Cystic fibrosis #Funding #LifeArc

£3m drug discovery programme for cystic fibrosis

UK-based Cystic fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) has announced a £3 million ($3.6 million) Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF. Funded by UK medical research charity LifeArc, the programme will support approximately… Read More

#News